February 2025 ASX Penny Stocks To Watch: Artrya, Nova, and More

As the ASX200 closed up 0.77% at 8,349 points and traders increased their bets on a February rate cut, attention turns to sectors like Materials and Financials that have shown resilience amid fluctuating inflation rates. In this context, investors might find opportunities in penny stocks—small or newer companies that can offer unique growth potential despite being a niche market segment. While the term "penny stocks" may seem outdated, these investments still hold promise when backed by strong financial health and strategic positioning within their industries.



Top 10 Penny Stocks In Australia
Name Share Price Market Cap Financial Health Rating
Embark Early Education (ASX:EVO) A$0.775 A$142.2M ★★★★☆☆
LaserBond (ASX:LBL) A$0.565 A$66.23M ★★★★★★
SHAPE Australia (ASX:SHA) A$2.88 A$237.13M ★★★★★★
Austin Engineering (ASX:ANG) A$0.52 A$328.68M ★★★★★☆
Vita Life Sciences (ASX:VLS) A$1.915 A$106.54M ★★★★★★
Helloworld Travel (ASX:HLO) A$2.01 A$332.15M ★★★★★★
SKS Technologies Group (ASX:SKS) A$1.59 A$228.62M ★★★★★★
Navigator Global Investments (ASX:NGI) A$1.61 A$796.38M ★★★★★☆
IVE Group (ASX:IGL) A$2.08 A$322.17M ★★★★☆☆
Servcorp (ASX:SRV) A$4.93 A$492.34M ★★★★☆☆

Click here to see the full list of 1,051 stocks from our ASX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.

Atlas Pearls (ASX:ATP)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Atlas Pearls Limited is engaged in the production and sale of South Sea pearls in Australia and Indonesia, with a market cap of A$63.17 million.
Operations: The company's revenue segments consist of Loose Pearl sales generating A$39.77 million in Australia and A$25.03 million in Indonesia.
Market Cap: A$63.17M
Atlas Pearls Limited, with a market cap of A$63.17 million, has demonstrated significant earnings growth of 246.3% over the past year, surpassing its five-year average and outperforming the luxury industry. The company benefits from a strong financial position with A$40.1 million in short-term assets covering both short and long-term liabilities, and it is debt-free. Despite shareholder dilution over the past year, Atlas Pearls maintains an outstanding return on equity of 56.7%. Its experienced board and management team contribute to stable operations while its high profit margins reflect improved profitability compared to last year.



Dive into the specifics of Atlas Pearls here with our thorough balance sheet health report.
Review our historical performance report to gain insights into Atlas Pearls' track record.

Artrya Limited (ASX: AYA)
Artrya Limited (ASX: AYA) has made significant strides towards commercializing its Salix software, focusing on the U.S. market while expanding its footprint in Australia. Over the past year, the company prioritized re-engaging with the FDA to secure necessary approvals and preparing for entry into the U.S. healthcare system. In June 2023, Artrya, among the best growth stocks to buy now, held a Q-Sub meeting with the FDA, where a roadmap was agreed upon to support its regulatory journey. The company has since submitted a 510(k) application for its Salix Coronary Anatomy (SCA) product, with clearance expected in the first half of 2025. Strategic partnerships with three prominent U.S. hospital groups, representing over 15,000 CCTA scans annually, have been established to test the software and streamline its integration into clinical workflows. AYA is among the top growth stocks as it sets the stage for revenue generation post-FDA clearance.

Nova Minerals limited (ASX: NVA)
Nova Minerals limited (ASX: NVA) has delivered impressive results from its Stibium Antimony-Gold prospect, confirming the area as a high-value exploration target. Announced on December 11, 2024, recent rock chip sampling revealed exceptional gold grades of up to 141 g/t Au and notable antimony concentrations, with earlier assays showing up to 60.5%. Spanning an 800m by 400m zone, Stibium presents significant exploration potential and is poised to be a prime drilling candidate for 2025, supported by favourable market conditions for both gold and antimony. The Estelle Gold and Critical Minerals Project in Alaska is rapidly becoming one of North America’s most promising mining districts. Covering 514km² with a 35km-long mineralized corridor, the project benefits from Alaska’s supportive regulatory environment and proximity to essential infrastructure, including the proposed West Susitna Access Road. Nova is exploring innovative power solutions, such as micro-nuclear reactors and grid connectivity, to enhance the project’s long-term viability. The RPM zone within Estelle continues to shine, with 2024 drilling revealing over 20 significant intercepts exceeding 5 g/t Au, including a peak grade of 52.7 g/t Au. Importantly, all drill holes ended in mineralization, highlighting the potential for resource expansion and positioning RPM as a key component of a future starter mine.



Less than 5% of the Estelle property has been explored, leaving substantial upside across other targets like Korbel, Muddy Creek, and Stoney. Korbel offers a large-scale, low-strip-ratio gold deposit with high-grade potential at Cathedral, while Muddy Creek’s high-grade zone has expanded, yielding rock samples up to 128.5 g/t Au. The discovery of antimony, copper, and other critical minerals enhances the project’s overall value and positions Nova is one of the growing companies to invest in, as it is likely to benefit from U.S. government initiatives focused on securing domestic critical mineral supplies.

Despite fluctuating revenues and recent losses, Nova Minerals remains strategically positioned for long-term growth. The Estelle Project’s multi-mineral potential, combined with consistent exploration success, aligns with the rising demand for both gold and critical minerals, making Nova an attractive player in the resource development sector.

Source: Company’s Report

ASX dividend stocks can be a great choice for building a source of passive income, and a significant portion of my portfolio is aimed at dividend-paying businesses. By owning ASX dividend shares, I can receive a (hopefully growing) flow of dividends from my holdings. Picking the right investments at the right price could also lead to capital growth, so ASX dividend stocks could be a contender for appealing total returns.

One of the benefits of investing in sold-off businesses is that the dividend yield has been pushed up. For example, if the share price of a business with a 5% dividend yield drops 10%, then the yield becomes 5.5%. With that in mind, below are two of the ideas I'm thinking about investing in.

Premier Investments Ltd (ASX: PMV)
Premier Investments recently sold its apparel brands business to Myer Holdings Ltd (ASX: MYR) and I think the transaction has increased the quality of the overall business. The retailer still owns Peter Alexander, Smiggle and its shareholding of Breville Group Ltd (ASX: BRG). Premier Investments also recently divested its holding of Myer shares. In my view, the retained businesses all have compelling long-term potential because they're expanding overseas, which lengthens their growth runways. The ASX dividend stock is a smaller business now, so its profit generation ability is probably lower, at least in the short term. The company was an appealing ASX dividend share before the split-up, and I think it will remain so, with greater growth potential. Based on the broker UBS' estimates for FY25, Premier Investments could pay a grossed-up dividend yield of 5.75%, including franking credits.

Centuria Capital Group (ASX: